| Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer (NCT07018063) | zhoujing | 2025-10-01 |
| Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations (NCT06392841) | Qian Qin | 2025-10-01 |
| Penfluridol for Relapsed/Refractory Small Cell Cancers (NCT07206563) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2025-10-01 |
| Human Induced Neural Stem Cell-derived Exosomes for Treating Acute Ischemic Stroke (NCT07143786) | Xuanwu Hospital, Beijing | 2025-10-01 |
| Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study) (NCT07089719) | Assistance Publique - Hôpitaux de Paris | 2025-10-01 |
| Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study (NCT07150416) | The First Affiliated Hospital of Guangzhou Medical University | 2025-10-01 |
| Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer. (NCT06364267) | Andrea DeCensi | 2025-10-01 |
| SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response (NCT07129187) | Chuan Wang | 2025-10-01 |
| Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study (NCT07189793) | First Affiliated Hospital of Wenzhou Medical University | 2025-10-01 |
| Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer (NCT07007182) | Jinbo Yue | 2025-10-01 |
| Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer (NCT07177716) | L & L Bio Co., Ltd., Ningbo, China | 2025-10-01 |
| The IVO-LUNG Study (NCT07204548) | Sun Yat-sen University | 2025-10-01 |
| Ketamine Assisted Psychotherapy for Treating Comorbid Chronic Pain and PTSD (NCT07009158) | Queen's University | 2025-10-01 |
| Preliminary Clinical Study of the Effectiveness and Safety of Ocular Surface Microbiota Transplantation in the Treatment of Dry Eye Disease (NCT07298811) | Second Affiliated Hospital of Nanchang University | 2025-10-01 |
| Safety and Feasibility of a Self-Balancing Exoskeleton for Rehabilitation in the Thoracic Surgical Intensive Care Unit: a Pilot Trial (NCT07220733) | Wandercraft | 2025-10-01 |
| Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint (NCT04750252) | Akan Biosciences, LLC | 2025-10-01 |
| G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma (NCT07184788) | Navy General Hospital, Beijing | 2025-10-01 |
| Clinical Efficacy of Transarterial Chemoembolization in Elderly Patients With Advanced Unresectable Colorectal Cancer (NCT07209384) | Junpeng Wang | 2025-10-01 |
| Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis (NCT06961383) | NeuroGenesis Ltd. | 2025-10-01 |
| [99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression (NCT07275463) | Tomsk National Research Medical Center of the Russian Academy of Sciences | 2025-10-01 |
| Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants (NCT07058025) | Ottawa Hospital Research Institute | 2025-10-01 |
| A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer (NCT07209449) | Memorial Sloan Kettering Cancer Center | 2025-10-01 |
| A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder (NCT06710431) | Afasci Inc | 2025-10-01 |
| Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder (NCT05999240) | New York State Psychiatric Institute | 2025-10-01 |
| Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer (NCT07104110) | Qilu Pharmaceutical Co., Ltd. | 2025-10-01 |
| A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations (NCT07178717) | Vall d'Hebron Institute of Oncology | 2025-10-01 |
| A Study of Single Dose of LP-003 in Adolescent Subjects (NCT07148557) | Longbio Pharma | 2025-10-01 |
| Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine) (NCT07214285) | University Hospital, Lille | 2025-10-01 |
| Study of COYA 302 for the Treatment of ALS (NCT07161999) | Coya Therapeutics | 2025-10-01 |
| Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization. (NCT07329686) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2025-10-01 |
| Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer (NCT07013851) | Grupo Español de Investigación en Cáncer de Ovario | 2025-10-01 |
| Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma (NCT07209163) | Ruijin Hospital | 2025-10-01 |
| Topical Imiquimod Treatment of Oral Dysplasia (NCT07210775) | University of Southern California | 2025-10-01 |
| ENgineered Tissue Repair of BronchopleUral FiSTula (NCT04435249) | Videregen Limited | 2025-10-01 |
| A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma. (NCT07205185) | Fudan University | 2025-10-01 |
| Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor (NCT06556862) | Beijing 302 Hospital | 2025-10-01 |
| A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY) (NCT07175038) | AllRock Bio, Inc. | 2025-10-01 |
| Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC (NCT07139041) | Chang Chen | 2025-10-01 |
| Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors (NCT07110584) | ModeX Therapeutics, An OPKO Health Company | 2025-10-01 |
| EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial (NCT07187284) | Zhongda Hospital | 2025-09-30 |
| Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH) (NCT07198386) | Cascade Pharmaceuticals, Inc | 2025-09-30 |
| Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle) (NCT06970106) | PYC Therapeutics | 2025-09-30 |
| Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder (NCT07220460) | AbbVie | 2025-09-30 |
| A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma (NCT07116616) | ModernaTX, Inc. | 2025-09-30 |
| Dose-Ranging Study of LQ036 Single-Domain Antibody Nebulization Solution in Poorly Controlled Asthma (NCT07589439) | Shanghai Novamab Biopharmaceuticals Co., Ltd. | 2025-09-30 |
| A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases (NCT07177950) | Peking University Cancer Hospital & Institute | 2025-09-30 |
| Vebreltinib for Advanced or Metastatic CCS (NCT07153887) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2025-09-30 |
| Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old (NCT07187375) | Neurocrine Biosciences | 2025-09-30 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases (NCT07161193) | Hebei Senlang Biotechnology Inc., Ltd. | 2025-09-30 |
| Study of Novel Therapeutics for Acute Remedy of Colitis (NCT06420492) | Brigham and Women's Hospital | 2025-09-30 |
| A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors (NCT07130383) | Minghui Pharmaceutical (Hangzhou) Ltd | 2025-09-30 |
| A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) (NCT07145151) | The United Bio-Technology (Hengqin) Co., Ltd. | 2025-09-30 |
| Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma (NCT07285590) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2025-09-30 |
| A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances (NCT06685965) | Reconnect Labs | 2025-09-30 |
| LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study (NCT07312422) | Zhejiang Provincial People's Hospital | 2025-09-30 |
| A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol (NCT07487909) | Sen-Jam Pharmaceutical | 2025-09-30 |
| Extended-field Proton Therapy for Cervical Cancer (NCT07298642) | National Taiwan University Hospital | 2025-09-30 |
| pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer (NCT07115927) | University College, London | 2025-09-30 |
| A Study to Evaluate the Tolerability, Safety and Efficacy of GNR-097 Gene Therapy in Pediatric Patients With Duchenne Muscular Dystrophy (NCT07673809) | AO GENERIUM | 2025-09-30 |
| Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) (NCT07204275) | Vertex Pharmaceuticals Incorporated | 2025-09-30 |
| A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy (NCT07176702) | Shanghai Zhongshan Hospital | 2025-09-30 |
| Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder (NCT06521476) | Sanjay R Patel | 2025-09-30 |
| An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (NCT07197866) | Teva Branded Pharmaceutical Products R&D LLC | 2025-09-30 |
| Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) (NCT07156604) | Fudan University | 2025-09-30 |
| SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer (NCT07125950) | Henan Cancer Hospital | 2025-09-30 |
| SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment (NCT07182721) | Fudan University | 2025-09-30 |
| A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1 (NCT07179640) | Alesta Therapeutics | 2025-09-30 |
| Circulating Tumor DNA (NCT06923527) | Yale University | 2025-09-30 |
| Reducing Systemic Inflammation in People on Antiretroviral Therapy (NCT07030920) | Centre hospitalier de l'Université de Montréal (CHUM) | 2025-09-30 |
| A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer (NCT07192614) | AstraZeneca | 2025-09-30 |
| Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia (NCT07095127) | Nuvig Therapeutics, Inc. | 2025-09-30 |
| Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC (NCT07200154) | Peking University Cancer Hospital & Institute | 2025-09-30 |
| Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy (NCT07106762) | Bristol-Myers Squibb | 2025-09-30 |
| Safety and Efficacy of wSp Vaccine in Young Children (NCT07216430) | Serum Life Science Europe GmbH | 2025-09-29 |
| Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia (NCT07037836) | Bastiaan Driehuys | 2025-09-29 |
| A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) (NCT07082192) | Shanghai Zhimeng Biopharma, Inc. | 2025-09-29 |
| 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC (NCT07043270) | Dartmouth-Hitchcock Medical Center | 2025-09-29 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) (NCT06979336) | Genentech, Inc. | 2025-09-29 |
| A Study of AAVB-039 in Participants With Stargardt Disease (STGD1) (NCT07161544) | AAVantgarde Bio Srl | 2025-09-29 |
| Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction (NCT07489534) | Daihong Liu | 2025-09-29 |
| A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL) (NCT07011576) | SCRI Development Innovations, LLC | 2025-09-29 |
| QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma (NCT06939855) | Sun Yat-sen University | 2025-09-28 |
| Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) (NCT07289997) | Hebei Medical University Fourth Hospital | 2025-09-28 |
| A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis (NCT07150988) | Haisco Pharmaceutical Group Co., Ltd. | 2025-09-26 |
| Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer (NCT07046078) | Fred Hutchinson Cancer Center | 2025-09-26 |
| The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma (NCT07290010) | Hebei Medical University Fourth Hospital | 2025-09-26 |
| IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx (NCT07196540) | Sun Yat-sen University | 2025-09-26 |
| Effect of Ketone Esters on Liver Fat Content and Metabolic Function (NCT07097506) | Washington University School of Medicine | 2025-09-26 |
| A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) (NCT07133633) | Merck Sharp & Dohme LLC | 2025-09-26 |
| Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors (NCT07071103) | Chuangzhen Chen | 2025-09-26 |
| Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months (NCT06723717) | Fondation Ophtalmologique Adolphe de Rothschild | 2025-09-26 |
| Daratumumab for Polyneuropathy Associated With MGUS (NCT06046287) | Georgetown University | 2025-09-26 |
| Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma (NCT07039162) | Ming-Yu Lien | 2025-09-26 |
| To Evaluate the Safety, Efficacy and Kinetic Characteristics of TRD205 Tablets for Postoperative Analgesia After Unilateral Hip Arthroplasty (NCT07121101) | Beijing Tide Pharmaceutical Co., Ltd | 2025-09-26 |
| EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease (NCT07168603) | ASTEROGENE Biomedical Co. Ltd. | 2025-09-26 |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (NCT07129993) | Daiichi Sankyo | 2025-09-26 |
| Study of DM-101PX in Adults With Birch Pollen Allergy (NCT07254871) | Desentum Oy | 2025-09-26 |
| Immunotherapy With Adaptive Pulse Radiotherapy in Solid Tumors (NCT07381231) | Samsung Medical Center | 2025-09-26 |
| A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol (NCT07199309) | Marea Therapeutics | 2025-09-26 |
| A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa (NCT07077902) | Tulane University | 2025-09-25 |